Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001397 · ClinicalTrials.gov registry record

Evaluation, Treatment, and Training for Patients With Blood Disorders

A clinical trial of Hematologic Diseases, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
1,452
Enrollment target
1
Study location

NCT00001397 is a study of Hematologic Diseases that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,452 participants, below the 2,153-participant average among 17 other Hematologic Diseases trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001397, a study of Hematologic Diseases, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
1,452 participants
Enrollment target
1
Study location

Study Summary

This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) or not being screened for participation in a study. The purpose of this study is to allow investigation into the blood disorders of patients in order to teach, learn, and gather more information about diseases of the blood. In addition, this study allows researchers the opportunity to evaluate patients referred to the Hematology Branch of the NHLBI with rare or undiagnosed diseases of the blood. This may be potentially beneficial to the patient and at the same time contribute to the development of new research ideas.

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 1,452 participants
Start Date 1993-11-08
Est. Completion 2020-10-05

What the Registry Record Tells You About NCT00001397

The ClinicalTrials.gov registry entry for NCT00001397 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,452 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,153-participant average among 17 other Hematologic Diseases trials with a reported enrollment target (33% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hematologic Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT00001397 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00001397 about?

NCT00001397 is a clinical study titled "Evaluation, Treatment, and Training for Patients With Blood Disorders". This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) or not being screened for participation in a s...

What is the current status of trial NCT00001397?

This trial is currently completed. The enrollment target is 1,452 participants. The study started on 1993-11-08. Estimated completion is 2020-10-05.

What conditions does trial NCT00001397 study?

This clinical trial studies the following conditions: Hematologic Diseases.

Who is sponsoring clinical trial NCT00001397?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001397 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.